Results 171 to 180 of about 2,468 (182)

Idarucizumab for dabigatran reversal: the first 6 months in a tertiary centre

Internal Medicine Journal, 2019
Andrew Borrie, Matthew Wheeler
exaly  

A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran

Thrombosis and Haemostasis, 2015
Stephan Glund, Joanne van Ryn, Paul Reilly   +2 more
exaly  

Dabigatran etexilate/idarucizumab

Reactions Weekly
  +5 more sources

Lessons learnt from local real‐life experience with idarucizumab for the reversal of dabigatran

Internal Medicine Journal, 2019
Jennifer Curnow, Leonardo Pašalić
exaly  

Incomplete dabigatran reversal with idarucizumab

Clinical Toxicology, 2018
Aaron Steele
exaly  

Acute reversal of dabigatran with Idarucizumab for intravenous thrombolysis as acute stroke treatment

Journal of Clinical Neuroscience, 2019
Dawn M Meyer
exaly  

Pharmacokinetics of idarucizumab and its target dabigatran in patients requiring urgent reversal of the anticoagulant effect of dabigatran

Journal of Thrombosis and Haemostasis, 2019
Stephan Glund
exaly  

Concerns about idarucizumab for dabigatran reversal

Blood Coagulation & Fibrinolysis, 2016
Claudia, Stöllberger, Peter, Pommer, Birke, Schneider, Josef, Finsterer   +3 more
openaire   +2 more sources

Idarucizumab does not have procoagulant effects: Assessment of thrombosis biomarkers in healthy volunteers

Thrombosis and Haemostasis, 2017
Stephan Glund, Paul Reilly, Joachim Stangier   +2 more
exaly  

Dabigatran-induced nephropathy and its successful treatment with Idarucizumab - case report and literature review

Thrombosis Research, 2018
Alexander Rabinovich, Iftach Sagy, Leonid Barski   +2 more
exaly